ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008
Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Transcription factor activity-based stratification reveals prognostic subtypes and immune landscape in neuroblastoma.Translational pediatrics · 2025Article
- Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma-research by one institute.Acta biochimica Polonica · 2024Article
- New insights in pediatrics in 2021: choices in allergy and immunology, critical care, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, neurology, nutrition, palliative care, respiratory tract illnesses and telemedicine.Italian journal of pediatrics · 2022Review
- Bioinformatics analysis of recurrent deletion regions in neuroblastoma.Medical oncology (Northwood, London, England) · 2022Article
- Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma.Frontiers in neuroinformatics · 2022Article
- Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.Nature communications · 2021Article
- Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities.Current treatment options in oncology · 2021Review
- Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.Italian journal of pediatrics · 2021Article
- Circulating tumor cells detection in neuroblastoma patients by EpCAM-independent enrichment and immunostaining-fluorescence in situ hybridization.EBioMedicine · 2018Article
- High genomic instability predicts survival in metastatic high-risk neuroblastoma.Neoplasia (New York, N.Y.) · 2012Article
- Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins.PloS one · 2012Article
- Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma.BMC cancer · 2009Article
- The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.Genome medicine · 2009Article
- New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics.Expert opinion on medical diagnostics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposePatients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease. The goal of this study is to develop a DNA copy number-based prognostic profile for these patients. EXPERIMENTAL
designWe have used comparative genomic hybridization to identify genome copy number changes that can predict outcome in patients with stage IV neuroblastoma without MYCN amplification.
resultsA strong correlation of patient survival with the presence of whole chromosome changes (WCC >or=2) was observed, even in the group of patients older than 500 days at time of diagnosis. This novel prognostic marker showed a significant dependence on the date of diagnosis; patients with WCC >or=2 diagnosed after 1998 had a significantly higher probability of survival compared with those diagnosed earlier. At the same time, no such time dependence was found among the samples with WCC <2, suggesting that medical progress patients in recent years has particularly benefited those patients with a stage IV non-MYCN-amplified disease if WCC >or=2 were present.
conclusionsIn this pilot study, we present a novel prognostic marker for survival of high-risk neuroblastoma patients over the age of 500 days without MYCN amplification and diagnosed after 1998. Further validation study is required to establish this risk stratification for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.